Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
about
A reliable and feasible way to predict the benefits of Nivolumab in patients with non-small cell lung cancer: a pooled analysis of 14 retrospective studiesPretreatment hematological markers predict clinical outcome in cancer patients receiving immune checkpoint inhibitors: A meta-analysisNeutrophil-to-lymphocyte ratio after four weeks of nivolumab administration as a predictive marker in patients with pretreated non-small-cell lung cancer
P2860
Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Pretreatment advanced lung can ...... ed non-small cell lung cancer.
@en
Pretreatment advanced lung cancer inflammation index
@nl
type
label
Pretreatment advanced lung can ...... ed non-small cell lung cancer.
@en
Pretreatment advanced lung cancer inflammation index
@nl
prefLabel
Pretreatment advanced lung can ...... ed non-small cell lung cancer.
@en
Pretreatment advanced lung cancer inflammation index
@nl
P2093
P2860
P356
P1433
P1476
Pretreatment advanced lung can ...... ed non-small cell lung cancer.
@en
P2093
Akihiro Tamiya
Ayako Tanaka
Fumio Imamura
Hidekazu Suzuki
Kenji Nakahama
Motohiro Tamiya
Norio Okamoto
Shinji Atagi
Shun-Ichi Isa
Takako Inoue
P2860
P356
10.1002/CAM4.1234
P407
P577
2017-11-18T00:00:00Z